Physicians

Department / Division
Medicine / Medicine - Cardiology

Address
DUMC 3126
Durham, NC 27710

Appointment Telephone
919-681-5816

Office Telephone
919-681-2069

Fax Telephone
919-681-0811

Training

• MD, Royal College of Surgeons in Ireland, 1981

Residency

• General Internal Medicine, St. Laurence's Hospital, St. Vincent's Hospital (Ireland), 1981-1984

Fellowship

• Cardiology (Research), St. Laurence's Hospital (Ireland), 1984-1987
• Cardiology, Duke University Medical Center, 1987-1991

Other Training

• Fellow, American College of Cardiology
• Fellow, European Society of Cardiology
• Fellow, Royal College of Physicians (Ireland)
• Fellow, Society for Cardiovascular Angiography and Interventions

Clinical Interests
Interventional cardiology, treatment of advanced/complex coronary disease, and primary or secondary prevention

Research Interests
The main focus of my research is in the management of acute myocardial infarction. My focus has revolved around the use of interventional procedures such as balloon angioplasty, intra-aortic balloon pumping and other support devices for the management of patients with acute myocardial infarction. Through participating and designing a number of randomized trials, we have helped crystallize the management to sustain patency of the infarct-related coronary artery in acute myocardial infarction. Furthermore, I have conducted several large multi-center clinical trials on the use of intra-aortic counterpulsation and angioplasty to better understand the pathophysiology of interventional procedures. Another major focus has been in the area of risk stratification in acute myocardial infarction. Early observations done abroad have led me to use new cardiac markers to identify high and low risk patients. Further research in this area will integrate early and rapid triage along with monitoring of the effect of thrombolysis after reperfusion in patients. A patent in the latter category has already been issued. My continued focus in the performance of multi-center international clinical trials has allowed us to explore different treatment strategies for the management of acute myocardial infarction from an international prospective. We have also collected angioplasty data on nearly 6,000 patients from around North America to further explore international differences in the management of patients using percutaneous interventions.

Industry Relationships and Collaborations (What's this?)

This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.

• Abiomed, Inc.
• Boehringer Ingelheim
• Bristol-Myers Squibb
• Daiichi Sankyo Co., Ltd
• Datascope Corporation
• Eli Lilly & Co.
• Faculty Connection
• Gilead Sciences, Inc.
• Medicines Company
• Merck & Co. USA (not assoc'd with Merck KGaA)
• Pozen
• Roche
• Sanofi-Aventis
• WebMD

Representative Publications
Chen EW, Canto JG, Parsons LS, Peterson ED, Littrell KA, Every NR, Gibson CM, Hochman JS, Ohman EM, Cheeks M, Barron HV, . Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation. 2003 Aug 26;108(8):951-7. (2003) Abstract

Kaul P, Newby LK, Fu Y, Hasselblad V, Mahaffey KW, Christenson RH, Harrington RA, Ohman EM, Topol EJ, Califf RM, Van de Werf F, Armstrong PW, . Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients. J Am Coll Cardiol. 2003 Feb 5;41(3):371-80. (2003) Abstract

Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003 Aug 20;290(7):898-904. (2003) Abstract

Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Topol E, Wallentin L, Simoons ML, . Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial. Circulation. 2003 Jan 28;107(3):437-42. (2003) Abstract

Stone GW, Ohman EM, Miller MF, Joseph DL, Christenson JT, Cohen M, Urban PM, Reddy RC, Freedman RJ, Staman KL, Ferguson JJ 3rd. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation in acute myocardial infarction: the benchmark registry. J Am Coll Cardiol. 2003 Jun 4;41(11):1940-5. (2003) Abstract

Sánchez CD, Newby LK, Hasselblad V, McNulty SE, Storrow AB, Gibler WB, Garvey JL, Schreiber DH, Tucker JF, Ohman EM. Comparison of 30-day outcome, resource use, and coronary artery disease severity in patients with suspected coronary artery disease with and without diabetes mellitus assigned to chest pain units. Am J Cardiol. 2003 May 15;91(10):1228-30. (2003) Abstract

Al Suwaidi J, Reddan DN, Williams K, Pieper KS, Harrington RA, Califf RM, Granger CB, Ohman EM, Holmes DR Jr, , . Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002 Aug 20;106(8):974-80. (2002) Abstract

Anderson RD, White HD, Ohman EM, Wagner GS, Krucoff MW, Armstrong PW, Weaver WD, Gibler WB, Stebbins AL, Califf RM, Topol EJ. Predicting outcome after thrombolysis in acute myocardial infarction according to ST-segment resolution at 90 minutes: a substudy of the GUSTO-III trial. Global Use of Strategies To Open occluded coronary arteries. Am Heart J. 2002 Jul;144(1):81-8. (2002) Abstract

Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, Mahaffey KW, Newby LK, Califf RM, Simoons ML, Topol EJ, Berger P, Lauer MS. Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med. 2002 Jun 27;346(26):2047-52. (2002) Abstract

Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH Jr, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation. 2002 Sep 17;106(12):1470-6. (2002) Abstract

Brener SJ, Zeymer U, Adgey AA, Vrobel TR, Ellis SG, Neuhaus KL, Juran N, Ivanc TB, Ohman EM, Strony J, Kitt M, Topol EJ. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol. 2002 Feb 6;39(3):377-86. (2002) Abstract

Cantor WJ, Newby LK, Christenson RH, Tuttle RH, Hasselblad V, Armstrong PW, Moliterno DJ, Califf RM, Topol EJ, Ohman EM, . Prognostic significance of elevated troponin I after percutaneous coronary intervention. J Am Coll Cardiol. 2002 Jun 5;39(11):1738-44. (2002) Abstract

Christenson JT, Cohen M, Ferguson JJ 3rd, Freedman RJ, Miller MF, Ohman EM, Reddy RC, Stone GW, Urban PM. Trends in intraaortic balloon counterpulsation complications and outcomes in cardiac surgery. Ann Thorac Surg. 2002 Oct;74(4):1086-90; discussion 1090-1. (2002) Abstract

Gibler WB, Armstrong PW, Ohman EM, Weaver WD, Stebbins AL, Gore JM, Newby LK, Califf RM, Topol EJ, . Persistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience. Ann Emerg Med. 2002 Feb;39(2):123-30. (2002) Abstract

Newby LK, Alpert JS, Ohman EM, Thygesen K, Califf RM. Changing the diagnosis of acute myocardial infarction: implications for practice and clinical investigations. Am Heart J. 2002 Dec;144(6):957-80. (2002) Abstract

Savonitto S, Granger CB, Ardissino D, Gardner L, Cavallini C, Galvani M, Ottani F, White HD, Armstrong PW, Ohman EM, Pieper KS, Califf RM, Topol EJ, . The prognostic value of creatine kinase elevations extends across the whole spectrum of acute coronary syndromes. J Am Coll Cardiol. 2002 Jan 2;39(1):22-9. (2002) Abstract

Wong CK, White HD, Wilcox RG, Criger DA, Califf RM, Topol EJ, Ohman EM, . Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. Heart. 2002 Oct;88(4):357-62. (2002) Abstract

Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet. 2001 Apr 7;357(9262):1063-8. (2001) Abstract

Cantor WJ, Hellkamp AS, Peterson ED, Zidar JP, Cowper PA, Sketch MH Jr, Tcheng JE, Califf RM, Ohman EM. Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes? J Am Coll Cardiol. 2001 Jun 1;37(7):1883-90. (2001) Abstract

Christenson RH, Duh SH, Roe MT, Ohman EM. Determination of the falloff constant (k(f)) from modeling biochemical marker release: a new variable for discriminating therapies. Cardiovasc Toxicol. 2001;1(2):171-6. (2001) Abstract

Ferguson JJ 3rd, Cohen M, Freedman RJ Jr, Stone GW, Miller MF, Joseph DL, Ohman EM. The current practice of intra-aortic balloon counterpulsation: results from the Benchmark Registry. J Am Coll Cardiol. 2001 Nov 1;38(5):1456-62. (2001) Abstract

Greenbaum AB, Harrington RA, Hudson MP, MacAulay CM, Wilcox RG, Simoons ML, Berdan LG, Guerci A, Cokkinos DV, Kitt MM, Lincoff AM, Topol EJ, Califf RM, Ohman EM. Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. PURSUIT Investigators. J Am Coll Cardiol. 2001 Feb;37(2):492-8. (2001) Abstract

Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest. 2001 Jan;119(1 Suppl):64S-94S. (2001) Abstract

Hudson MP, Granger CB, Topol EJ, Pieper KS, Armstrong PW, Barbash GI, Guerci AD, Vahanian A, Califf RM, Ohman EM. Early reinfarction after fibrinolysis: experience from the global utilization of streptokinase and tissue plasminogen activator (alteplase) for occluded coronary arteries (GUSTO I) and global use of strategies to open occluded coronary arteries (GUSTO III) trials. Circulation. 2001 Sep 11;104(11):1229-35. (2001) Abstract

Newby LK, Ohman EM, Christenson RH, Moliterno DJ, Harrington RA, White HD, Armstrong PW, Van De Werf F, Pfisterer M, Hasselblad V, Califf RM, Topol EJ. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation. 2001 Jun 19;103(24):2891-6. (2001) Abstract

Newby LK, Storrow AB, Gibler WB, Garvey JL, Tucker JF, Kaplan AL, Schreiber DH, Tuttle RH, McNulty SE, Ohman EM. Bedside multimarker testing for risk stratification in chest pain units: The chest pain evaluation by creatine kinase-MB, myoglobin, and troponin I (CHECKMATE) study. Circulation. 2001 Apr 10;103(14):1832-7. (2001) Abstract

Ohman EM, Harrington RA, Cannon CP, Agnelli G, Cairns JA, Kennedy JW. Intravenous thrombolysis in acute myocardial infarction. Chest. 2001 Jan;119(1 Suppl):253S-277S. (2001) Abstract

Ohman EM, Peterson E. Implications and challenges using practice guidelines for chronic angina. Ann Intern Med. 2001 Oct 2;135(7):527-9. (2001) Abstract

Popma JJ, Ohman EM, Weitz J, Lincoff AM, Harrington RA, Berger P. Antithrombotic therapy in patients undergoing percutaneous coronary intervention. Chest. 2001 Jan;119(1 Suppl):321S-336S. (2001) Abstract

Roe MT, Ohman EM, Maas AC, Christenson RH, Mahaffey KW, Granger CB, Harrington RA, Califf RM, Krucoff MW. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol. 2001 Jan;37(1):9-18. (2001) Abstract

Singh M, Reeder GS, Ohman EM, Mathew V, Hillegass WB, Anderson RD, Gallup DS, Garratt KN, Holmes DR Jr. Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An Angiographic Trials Pool data experience. J Am Coll Cardiol. 2001 Sep;38(3):624-30. (2001) Abstract

Alexander JH, Sparapani RA, Mahaffey KW, Deckers JW, Newby LK, Ohman EM, Corbalán R, Chierchia SL, Boland JB, Simoons ML, Califf RM, Topol EJ, Harrington RA. Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. JAMA. 2000 Jan 19;283(3):347-53. (2000) Abstract

Herrmann HC, Moliterno DJ, Ohman EM, Stebbins AL, Bode C, Betriu A, Forycki F, Miklin JS, Bachinsky WB, Lincoff AM, Califf RM, Topol EJ. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 Pilot) Trial. J Am Coll Cardiol. 2000 Nov 1;36(5):1489-96. (2000) Abstract

Lincoff AM, Harrington RA, Califf RM, Hochman JS, Guerci AD, Ohman EM, Pepine CJ, Kopecky SL, Kleiman NS, Pacchiana CM, Berdan LG, Kitt MM, Simoons ML, Topol EJ. Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition. Insights from the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. Circulation. 2000 Sep 5;102(10):1093-100. (2000) Abstract

Menon V, Hochman JS, Stebbins A, Pfisterer M, Col J, Anderson RD, Hasdai D, Holmes DR, Bates ER, Topol EJ, Califf RM, Ohman EM. Lack of progress in cardiogenic shock: lessons from the GUSTO trials. Eur Heart J. 2000 Dec;21(23):1928-36. (2000) Abstract

Ohman EM, Granger CB, Harrington RA, Lee KL. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA. 2000 Aug 16;284(7):876-8. (2000) Abstract

Roe MT, Harrington RA, Prosper DM, Pieper KS, Bhatt DL, Lincoff AM, Simoons ML, Akkerhuis M, Ohman EM, Kitt MM, Vahanian A, Ruzyllo W, Karsch K, Califf RM, Topol EJ. Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease.The Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators. Circulation. 2000 Sep 5;102(10):1101-6. (2000) Abstract

Topol EJ, Ohman EM, Armstrong PW, Wilcox R, Skene AM, Aylward P, Simes J, Dalby A, Betriu A, Bode C, White HD, Hochman JS, Emanuelson H, Vahanian A, Sapp S, Stebbins A, Moliterno DJ, Califf RM. Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III Trial. Circulation. 2000 Oct 10;102(15):1761-5. (2000) Abstract

Cohen MG, Granger CB, Ohman EM, Stebbins AL, Grinfeld LR, Cagide AM, Elizari MV, Betriu A, Kong DF, Topol EJ, Califf RM. Outcome of Hispanic patients treated with thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I and III trials. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol. 1999 Nov 15;34(6):1729-37. (1999) Abstract

Anderson RD, Ohman EM, Holmes DR Jr, Harrington RA, Barsness GW, Wildermann NM, Phillips HR, Topol EJ, Califf RM. Prognostic value of congestive heart failure history in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol. 1998 Oct;32(4):936-41. (1998) Abstract

Gurbel PA, Serebruany VL, Shustov AR, Bahr RD, Carpo C, Ohman EM, Topol EJ. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III Investigators. Global Use of Strategies to Open Occluded Coronary Arteries. J Am Coll Cardiol. 1998 Jun;31(7):1466-73. (1998) Abstract

Newby LK, Christenson RH, Ohman EM, Armstrong PW, Thompson TD, Lee KL, Hamm CW, Katus HA, Cianciolo C, Granger CB, Topol EJ, Califf RM. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation. 1998 Nov 3;98(18):1853-9. (1998) Abstract

Barsness GW, Peterson ED, Ohman EM, Nelson CL, DeLong ER, Reves JG, Smith PK, Anderson RD, Jones RH, Mark DB, Califf RM. Relationship between diabetes mellitus and long-term survival after coronary bypass and angioplasty. Circulation. 1997 Oct 21;96(8):2551-6. (1997) Abstract

Christenson RH, Ohman EM, Topol EJ, Peck S, Newby LK, Duh SH, Kereiakes DJ, Worley SJ, Alosozana GL, Wall TC, Califf RM. Assessment of coronary reperfusion after thrombolysis with a model combining myoglobin, creatine kinase-MB, and clinical variables. TAMI-7 Study Group. Thrombolysis and Angioplasty in Myocardial Infarction-7. Circulation. 1997 Sep 16;96(6):1776-82. (1997) Abstract

Ohman EM, Tardiff BE. Periprocedural cardiac marker elevation after percutaneous coronary artery revascularization. Importance and implications. JAMA. 1997 Feb 12;277(6):495-7. (1997) Abstract

Ohman EM, Armstrong PW, Christenson RH, Granger CB, Katus HA, Hamm CW, O'Hanesian MA, Wagner GS, Kleiman NS, Harrell FE Jr, Califf RM, Topol EJ. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med. 1996 Oct 31;335(18):1333-41. (1996) Abstract

Weaver WD, White HD, Wilcox RG, Aylward PE, Morris D, Guerci A, Ohman EM, Barbash GI, Betriu A, Sadowski Z, Topol EJ, Califf RM. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. JAMA. 1996 Mar 13;275(10):777-82. (1996) Abstract